Skip to main content
Zai Lab Limited logo

Zai Lab Limited — Investor Relations & Filings

Ticker · 9688 ISIN · KYG9887T1168 LEI · 549300P2UYQ9U5LY1T58 HKEX Manufacturing
Open in API
Filings indexed 388 across all filing types
Latest filing 2021-12-16 Regulatory Filings
Country KY Cayman Islands
Listing HKEX 9688

About Zai Lab Limited

http://www.zailaboratory.com

Zai Lab Limited is an innovative, research-based, commercial-stage biopharmaceutical company dedicated to discovering, developing, and commercializing transformative therapies that address medical conditions with significant unmet needs. The company focuses its pipeline and development efforts across four core therapeutic areas: oncology, immunology, neuroscience, and infectious disease. Zai Lab employs a strategy of internal research and global partnerships to advance best-in-class and first-in-class medicines. A key commercial product is ZEJULA (niraparib), utilized as a maintenance treatment for ovarian cancer in markets including mainland China.

Recent filings

Filing Released Lang Actions
OVERSEAS REGULATORY ANNOUNCEMENT
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filing with the U.S. Securities and Exchange Commission, dated December 16, 2021, by Zai Lab Limited. It announces the approval of a new drug application (NUZYRA) by the China National Medical Products Administration (NMPA). The document includes a press release attached as an exhibit and details about the drug, its approval, and related clinical information. There are no financial statements or detailed financial performance data included. The document is an event-driven regulatory announcement about a significant corporate event (drug approval) rather than a financial report or earnings release. It is not a full annual or interim report, nor a call transcript or management discussion. The document fits best into the category of Regulatory Filings (RNS) as it is a current report disclosing a material event pursuant to SEC rules and Hong Kong Stock Exchange listing rules, without substantive financial data or detailed financial analysis.
2021-12-16 English
OVERSEAS REGULATORY ANNOUNCEMENT
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filing with the U.S. Securities and Exchange Commission dated December 3, 2021, by Zai Lab Limited. It announces an update to the National Reimbursement Drug List in China to include ZEJULA for ovarian cancer treatment. The document includes a press release as an exhibit and references the filing of the Form 8-K itself. The content is an event announcement related to regulatory and business developments, not a full financial report or earnings release. It is not a report publication announcement since the document itself is the filing. The document fits best under Regulatory Filings (RNS) as it is a current report filing disclosing a material event but does not contain financial statements or detailed financial analysis. Confidence is high due to the clear identification of the document as a Form 8-K and the nature of the content.
2021-12-03 English
Overseas Regulatory Announcement
Board/Management Information Classification · 100% confidence The document is a Form 8-K filing with the U.S. SEC reporting the appointment of a new independent director, Mr. Richard Gaynor, to the company's board and the formation of a new Board committee. It includes details about the director's compensation, indemnification, and background. The document is not a full annual or quarterly report, nor is it an earnings release or financial supplement. It is a regulatory announcement about changes in the company's board of directors. Therefore, it fits the category of Board/Management Information (MANG). The document length (14,410 characters) supports that it is a substantive announcement rather than a brief notice or report publication announcement.
2021-11-22 English
Overseas Regulatory Announcement
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filing with the U.S. Securities and Exchange Commission, dated November 8, 2021, by Zai Lab Limited. It reports entry into material definitive agreements (license and collaboration agreements with Blueprint Medicines and Karuna Therapeutics) and includes unaudited financial results for the three months ended September 30, 2021. The document contains detailed descriptions of the agreements, financial terms, and references to press releases and exhibits. It is not a full annual or quarterly report but a current report disclosing material events and financial updates. The presence of detailed contract terms and financial milestone payments indicates it is a regulatory announcement of material agreements and financial updates rather than a full financial report or earnings release. Therefore, the filing type best fitting this document is a Regulatory Filing (RNS), as it does not fit the definitions of other categories like Annual Report, Earnings Release, or Capital/Financing Update specifically. Confidence is high due to the clear identification as a Form 8-K and the nature of the content.
2021-11-10 English
Overseas Regulatory Announcement
Interim / Quarterly Report Classification · 100% confidence The document is a quarterly report on Form 10-Q for the third quarter ended September 30, 2021, filed with the U.S. Securities and Exchange Commission. It contains detailed financial statements, management discussion and analysis, risk factors, and other substantive financial information. The presence of unaudited condensed consolidated financial statements and management's discussion confirms it is a comprehensive interim financial report. The document is not a brief announcement or a certification but the actual quarterly report itself. Therefore, it fits the definition of an Interim / Quarterly Report (IR).
2021-11-10 English
ANNOUNCEMENT OF THE 2021 Q3 FINANCIAL RESULTS
Interim / Quarterly Report Classification · 95% confidence The document is titled 'ANNOUNCEMENT OF THE 2021 Q3 FINANCIAL RESULTS' and contains detailed financial results and corporate updates for the third quarter ended September 30, 2021. It includes extensive discussion of product pipeline, recent product highlights, anticipated milestones, and financial performance commentary. The document is about 15,000 characters long, indicating it is a substantive report rather than a brief announcement. The content aligns with a comprehensive quarterly financial report containing actual financial data and analysis, not merely a summary or announcement. Therefore, the document fits the definition of an Interim / Quarterly Report (IR).
2021-11-10 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.